Cardiff Oncology (CRDF) Competitors $4.26 -0.23 (-5.12%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRDF vs. PLRX, RLAY, AVXL, IMNM, KURA, KROS, TYRA, ERAS, CRON, and EOLSShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Pliant Therapeutics (PLRX), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Erasca (ERAS), Cronos Group (CRON), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Cardiff Oncology vs. Pliant Therapeutics Relay Therapeutics Anavex Life Sciences Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Erasca Cronos Group Evolus Pliant Therapeutics (NASDAQ:PLRX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment, valuation and community ranking. Which has preferable valuation and earnings, PLRX or CRDF? Cardiff Oncology has lower revenue, but higher earnings than Pliant Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M508.79-$161.34M-$3.34-3.96Cardiff Oncology$688K316.61-$41.44M-$0.94-4.53 Do analysts recommend PLRX or CRDF? Pliant Therapeutics currently has a consensus target price of $40.50, indicating a potential upside of 206.59%. Cardiff Oncology has a consensus target price of $10.33, indicating a potential upside of 142.57%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor PLRX or CRDF? Pliant Therapeutics received 34 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 74.26% of users gave Pliant Therapeutics an outperform vote while only 64.06% of users gave Cardiff Oncology an outperform vote. CompanyUnderperformOutperformPliant TherapeuticsOutperform Votes7574.26% Underperform Votes2625.74% Cardiff OncologyOutperform Votes4164.06% Underperform Votes2335.94% Which has more risk and volatility, PLRX or CRDF? Pliant Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Does the media prefer PLRX or CRDF? In the previous week, Cardiff Oncology had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Cardiff Oncology and 1 mentions for Pliant Therapeutics. Cardiff Oncology's average media sentiment score of 0.49 beat Pliant Therapeutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PLRX or CRDF more profitable? Pliant Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,238.17%. Pliant Therapeutics' return on equity of -48.91% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -48.91% -41.09% Cardiff Oncology -6,238.17%-73.97%-60.40% Do insiders & institutionals believe in PLRX or CRDF? 97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by company insiders. Comparatively, 7.8% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryPliant Therapeutics beats Cardiff Oncology on 13 of the 19 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDF vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$217.83M$2.94B$5.13B$9.08BDividend YieldN/A1.90%4.93%4.22%P/E Ratio-4.5346.7389.6617.18Price / Sales316.61415.011,115.28116.98Price / CashN/A182.1042.8237.86Price / Book2.733.894.794.78Net Income-$41.44M-$42.21M$120.04M$225.60M7 Day Performance8.67%-2.15%-1.91%-1.23%1 Month Performance70.40%4.20%11.48%3.36%1 Year Performance187.84%18.39%30.60%16.60% Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDFCardiff Oncology2.0224 of 5 stars$4.26-5.1%$10.33+142.6%+195.8%$217.83M$688,000.00-4.5320PLRXPliant Therapeutics3.3658 of 5 stars$13.65+2.6%$40.50+196.7%-19.0%$830.60M$1.58M0.0090RLAYRelay Therapeutics2.2525 of 5 stars$4.88+3.6%$20.50+320.1%-60.4%$816.81M$25.55M-1.80304Insider TradeAVXLAnavex Life Sciences3.3412 of 5 stars$9.35+10.5%$43.00+359.9%-2.5%$792.88MN/A-18.3640IMNMImmunome2.5635 of 5 stars$12.47-0.9%$28.83+131.2%+33.0%$778.34M$10.13M-1.5540Positive NewsKURAKura Oncology4.4841 of 5 stars$9.94+3.2%$29.38+195.5%-27.0%$772.93MN/A-4.08142KROSKeros Therapeutics3.2934 of 5 stars$18.88+0.3%$81.33+330.8%-49.6%$764.77M$651,000.00-3.61100Gap DownHigh Trading VolumeTYRATyra Biosciences2.0686 of 5 stars$14.90-0.3%$31.00+108.1%+2.0%$753.94MN/A-9.2820ERASErasca2.0792 of 5 stars$2.62+2.3%$5.90+125.2%+35.8%$740.75MN/A-3.08126News CoveragePositive NewsCRONCronos Group1.8534 of 5 stars$1.92-0.4%$3.00+56.1%+4.8%$734.86M$87.24M-15.19356News CoverageEOLSEvolus3.8293 of 5 stars$11.51flat$23.00+99.8%+12.5%$728.81M$202.09M-12.73170 Related Companies and Tools Related Companies PLRX Competitors RLAY Competitors AVXL Competitors IMNM Competitors KURA Competitors KROS Competitors TYRA Competitors ERAS Competitors CRON Competitors EOLS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRDF) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
